Product development

Synaffix is a biotechnology company enabling highly-competitive targeted cancer therapeutics using its site-specific antibody-drug conjugate (ADC) technology platform. The platform consistently delivers more effective and better tolerated ADCs compared to all 3 major clinical-stage technologies.

The business model of Synaffix is technology out-licensing where granted patents provide end-to-end protection of the technology and resulting product candidates thru at least 2035.

We anticipate the first-in-human studies evaluating Synaffix ADC technology to be initiated by our partners in 2018.

Area of work

Oncology, Antibody Drug Conjugates

News from Synaffix

Synaffix Announces 3rd License Taken by ADC Therapeutics

29 May 19
READ MORE

Voucher gives rise to collaboration

23 Apr 19
READ MORE

Synaffix Announces License Agreement worth up to $125 million with Leading Chinese ADC Developer, Shanghai Miracogen

11 Apr 19
READ MORE